IGFBP-3 treatment has been shown to stimulate human primary lung fibroblasts to produce tenascin-C and Collagen 1, supporting a role for IGFBP-3 in promoting ECM deposition in pulmonary fibrosis (Figure 3A) [112]. The gene discussed is IGFBP3; the disease is pulmonary fibrosis.